Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Chemomab Therapeutics Ltd. - American Depositary Shares
(NQ:
CMMB
)
1.430
+0.130 (+10.00%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Chemomab Therapeutics Ltd. - American Depositary Shares
< Previous
1
2
3
4
5
6
Next >
Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 03, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
December 03, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
November 19, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
November 14, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
October 30, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
October 15, 2024
Via
Benzinga
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024
October 15, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Earnings Scheduled For November 14, 2024
↗
November 14, 2024
Via
Benzinga
Chemomab Therapeutics to Present at October 2024 Investor Conferences
October 01, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
September 03, 2024
Via
Benzinga
Chemomab Therapeutics to Present at September 2024 Investor Conferences
August 28, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024
↗
August 21, 2024
Chemomab Therapeutics just reported results for the second quarter of 2024.
Via
InvestorPlace
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 21, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
August 12, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
July 30, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
July 26, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise
↗
July 25, 2024
Chemomab Therapeutics reports successful Phase 2 SPRING trial results for CM-101 in primary sclerosing cholangitis, showing safety and efficacy. Key findings include significant improvements in liver...
Via
Benzinga
Chemomab Therapeutics Announces $10 Million Private Placement
July 25, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
July 25, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
June 18, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
June 06, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
May 17, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024
↗
May 09, 2024
Chemomab Therapeutics just reported results for the first quarter of 2024.
Via
InvestorPlace
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
May 08, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
↗
May 06, 2024
Via
Benzinga
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
May 02, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
April 24, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
April 18, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
April 02, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
